Ultragenyx Pharmaceutical Inc
RARE
View Detailed Chart
19.850USD
+1.350+7.30%
Close 03/25, 16:00（ET）Quotes delayed by 15 min
576.88MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.30%
5 Days
-2.98%
1 Month
-13.36%
6 Months
-28.65%
Year to Date
-13.70%
1 Year
-48.69%
View Detailed Chart
TradingKey Stock Score of Ultragenyx Pharmaceutical Inc
Currency: USD Updated: 2026-03-25Key Insights
Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.32.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ultragenyx Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ultragenyx Pharmaceutical Inc Highlights
StrengthsRisks
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.98% year-on-year.
Overvalued
The company’s latest PE is -3.40, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.29M shares, decreasing 2.15% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 198.70K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.41.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
51.316
Target Price
+153.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ultragenyx Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ultragenyx Pharmaceutical Inc Info
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ticker SymbolRARE
CompanyUltragenyx Pharmaceutical Inc
CEOKakkis (Emil D)
Websitehttps://www.ultragenyx.com/
Related Instruments
+1.47%
+0.11%
+1.98%
+0.73%
+2.58%
+0.96%
+1.44%
+1.58%
-0.25%
+1.19%
-1.52%
+3.31%
+1.97%
+2.70%
+1.42%
0.00%
+1.97%
+1.05%
+0.67%
+1.39%Popular Symbols
252.620
+0.980 (+0.39%)
178.680
+3.480 (+1.99%)
69860.420
-1119.080 (-1.58%)
296.140
-4.910 (-1.63%)
2114.060
-49.930 (-2.31%)
385.950
+2.920 (+0.76%)
4429.610
-75.830 (-1.68%)
93.332
+2.393 (+2.63%)
1.156
+0.000 (+0.00%)
159.482
+0.023 (+0.01%)
